Limitations of current Parkinson's disease therapy
Citations Over TimeTop 10% of 2003 papers
Abstract
Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the "honeymoon" period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from "dopa-resistant" motor symptoms (speech impairment, abnormal posture, gait and balance problems), "dopa-resistant" nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug-related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety.
Related Papers
- → Dopaminergic augmentation of restless legs syndrome(2010)107 cited
- → Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep(2003)36 cited
- → Levodopa in Parkinson??s Disease(1999)33 cited
- → Peripheral dopaminergic nerves(1989)12 cited
- Levodopa - from parkinson's disease to restless legs?(2011)